At the subsequent visit, people are reviewed by a consultant rheumatologist with access to all results, and assigned an initial clinical diagnosis from a dropdown menu of possibilities that includes “ACPA+ arthralgia.” Individuals placed in this category by their consulting rheumatologist (confirmed to have 0 recorded swollen joints out of a total of 74 assessed and a positive anti-CCP2 test result according to routine laboratory testing are defined eligible for inclusion in the “At-Risk of RA” NEAC sub-cohort (Table 2). The gene discussed is AGBL2; the disease is rheumatoid arthritis.